Selvita SA
WSE:SLV
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Selvita SA
Revenue
Selvita SA
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
S
|
Selvita SA
WSE:SLV
|
Revenue
zł337.3m
|
CAGR 3-Years
23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
I
|
Inno-Gene SA
WSE:IGN
|
Revenue
zł1.2m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-9%
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Revenue
zł4.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Revenue
zł55.6m
|
CAGR 3-Years
88%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
See Also
What is Selvita SA's Revenue?
Revenue
337.3m
PLN
Based on the financial report for Mar 31, 2024, Selvita SA's Revenue amounts to 337.3m PLN.
What is Selvita SA's Revenue growth rate?
Revenue CAGR 3Y
23%
Over the last year, the Revenue growth was -18%. The average annual Revenue growth rates for Selvita SA have been 23% over the past three years .